{"title": "PDF", "author": "PDF", "url": "https://www.ladr.de/fileadmin/migrated/_02_pdfs/01_medizin/04_fortbildung/LADR_Webinar_Long-COVID_20221102_Immunologie_COVID-19_Erkrankung_Harald_Renz.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Immunologie der COVID-19 \nErkrankung \nProf. Dr. med. Harald Renz\nInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics Philipps University \nMarburg University Hospital Giessen and Marburg GmbH\nHarald.Renz@uk- gm.de\nReported deaths : 5.93 Mio,\nbut estimation of18.2 Miodeaths\nWang H, The Lancet, 2022\n-Keine SARS -CoV2 PCR\n-Keine Antigen -(Schnell -)Teste\n-Keine Antik\u00f6rper -Tests\n-Kein Impfstoff\n-Keine spezifischen Medikamente\n-Nicht ausreichend MaskenZu Beginn der Pandemie:Clinical manifestation of COVID -19\nDiamond et al., \nNature Immunology, 2022COVID- 19 and comorbidities \nLi et al., JACI 2020\nObesity a risk factor for more severe COVID -19\nGoldman B., Stanford Medicine, Photo by biorender.com, 2022An integrated working model ofCOVID -19 immunology and\ndisease severity (I)\nSette & Crotty et al., Cell 2021\nAn integrated working model ofCOVID -19 immunology and\ndisease severity (II)\nSette & Crotty et al., Cell 2021\nImmune responses for protection against COVID- 19\nBarouch, Dan H., N Engl J Med, 2022Global COVID- 19 vaccination rates (8 July 2022)\nBarouch, Dan H., N Engl J Med, 2022Barouch, Dan H., N Engl J Med, 2022Protective efficacy of COVID 2019 vaccines SARS -CoV-2 variant -specific neutralizing antibody responses \nin convalescent donors after 6 months \nand early after completion of the vaccination regimen\nGeurtsvanKessel et al., \nScience Immunology, 2022Protection and waning of natural and hybrid \nimmunity to SARS -CoV-2\nGoldberg et al., NEJM, 2022Protection and waning of natural and hybrid \nimmunity to SARS -CoV-2\nGoldberg et al., NEJM, 2022\nProtection and waning of natural and hybrid \nimmunity to SARS -CoV-2\nGoldberg et al., NEJM, 2022\nViral infections and Asthma / COPD exacerbation Reduction in asthma exacerbations across England \nover the first 18 months after the first lockdown\nShah et al., The Lancet Regional Health -Europe, 2022Childhood asthma outcomes were improved during \nthe first wave of the COVID- 19 pandemic\nPapadopoulos et al., Allergy, 2021The epidemiology of RSV detections in three\nAustralian states\nEden et al., Nature Communications, 20222017- 19 2020- 21SARS -CoV-2 variants over time \nBarouch, Dan H., N Engl J Med, 2022Timeline of post -acute COVID -19\nNalbandian et al., Nature Med 2021 Long COVID\n\u2022More common following severe acute COVID- 19\n\u2022More common with increasing age\n\u2022Further riskfactors arediabetes T2, EBV infection\n\u2022Vaccination protects partly\n\u2022Persistant inflammation\n\u2022Caused bypersisting hidden virus?\n\u2022Autoimmunity (anti -U1-suRNP; anti -SS-B/La)", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}